[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564821":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":10,"centralContacts":25,"locations":32,"responsibleParty":79,"collaborators":81,"id":86,"slug":87,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":88,"sex":94,"minAge":95,"maxAge":10,"enrollmentInfo":96,"targetDuration":10,"studyType":99,"phases":10,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":55,"whyStopped":10,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"Nantes University Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Study population",null,"The study population must correspond to the research inclusion criteria. A fibroscan will be performed on each patient enrolled in the study. Each participant will also be offered a biological sample for an ancillary study.",[13,14],"Diagnostic Test: Fibroscan","Other: Sample collection",[16,21],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":10},"DIAGNOSTIC_TEST","Fibroscan","Evaluation of the prevalence of steatosis by measuring ultrasound attenuation with Fibroscan® (non-invasive method, at a distance from a meal (3h fasting)).",[9],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"Sample collection","20 mL whole blood sample",[9],[26],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Sarra SMATI","CONTACT","02 53 48 27 19","+33","sarra.grangeon@chu-nantes.fr",[33,53,64],{"facility":34,"status":35,"city":36,"state":10,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"CHU angers","NOT_YET_RECRUITING","Angers","49933","France","FR",{"type":41,"coordinates":42},"Point",[43,44],-0.55202,47.47156,{"lat":44,"lon":43},[47,51],{"name":48,"role":28,"phone":49,"phoneExt":10,"email":50},"Sandrine LABOUREAU","02 41 35 45 93","sandrine.laboureau@chu-angers.fr",{"name":48,"role":52,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"facility":54,"status":55,"city":56,"state":10,"zip":10,"country":38,"countryCode":39,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"CHU Nantes","RECRUITING","Nantes",{"type":41,"coordinates":58},[59,60],-1.55336,47.21725,{"lat":60,"lon":59},[63],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},{"facility":65,"status":35,"city":66,"state":10,"zip":67,"country":38,"countryCode":39,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Rennes University Hospital","Rennes","35033",{"type":41,"coordinates":69},[70,71],-1.67431,48.11109,{"lat":71,"lon":70},[74,78],{"name":75,"role":28,"phone":76,"phoneExt":10,"email":77},"François PAILLARD, Dr","02.99.28.25.40","francois.paillard@chu-rennes.fr",{"name":75,"role":52,"phone":10,"phoneExt":10,"email":10},{"type":80,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[82,85],{"name":83,"class":84},"University Hospital, Angers","OTHER_GOV",{"name":65,"class":6},"100564821","assessment-of-the-prevalence-of-steatotic-liver-disease-associated-with-metabolic-dysfunction-in-patients-with-heterozygous-familial-hypercholesterolemia-100564821",false,"NCT06634160","Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With Heterozygous Familial Hypercholesterolemia","Assessment of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) Prevalence in Patients With Heterozygous Familial Hypercholesterolemia (HeFH): the STEATO-FH Study","STEATO-FH","Inclusion Criteria:\n\n* Patient aged 35 or over\n* Consultation at Nantes, Rennes or Angers University Hospital during the inclusion period\n* With a diagnosis of familial hypercholesterolemia defined by the presence of a genetic variant, ACMG classes 4 \\& 5 on LDLR, APOB or PCSK9\n* Patient not objecting to inclusion in study (no written objection)\n\nExclusion Criteria:\n\n* Protected patients: minors, adults under guardianship, curatorship and\u002For safeguard of justice\n* Pregnant or breast-feeding\n* Active viral hepatitis\n* Hemochromatosis\n* Other genetic or autoimmune hepatitis\n* Current treatment with a drug likely to cause hepatic steatosis, including amiodarone, carbamazepine, tamoxifen, valproate, clozapine, anti-retrovirals\n* Current oral corticosteroid therapy unless dose has been stable for ≥ 3 months\n* Current pathological alcohol consumption (≥ 60 g\u002Fday in men and ≥ 50 g\u002Fday in women)","ALL","35 Years",{"count":97,"type":98},200,"ESTIMATED","OBSERVATIONAL","The main goal of the STEATO-FH study is to determine the prevalence of liver steatosis within the Heterozygous Familial Hypercholesterolemia patient population.",[102],"Heterozygous Familial Hypercholesterolemia",[104,102,105,106],"MASLD","steatosis","fibrosis","2025-02-05",{"date":109,"type":110},"2025-02-06","ACTUAL",{"date":112,"type":110},"2025-01-30",{"date":114,"type":98},"2028-01-30",{"name":5,"class":6},3]